Related Experiment Video
Updated: Jul 4, 2026
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Scaled-down purification protocol to access proteomic analysis of 20S proteasome from human tissue samples:
Manuelle Ducoux-Petit1, Sandrine Uttenweiler-Joseph, Franck Brichory
1Universite de Toulouse, Institute of Pharmacology and Structural Biology, IPBS, UPS, 205 route de Narbonne, 31077, Toulouse, cedex 4, France.
Abstract:
The proteasome is a proteolytic complex that constitutes the main pathway for degradation of intracellular proteins in eukaryotic cells. It regulates many physiological processes and its dysfunction can lead to several pathologies like cancer. To study the 20S proteasome structure/activity relationship in cells that derive from human biopsy samples, we optimized an immuno-purification protocol for the analysis of samples containing a small number of cells using magnetic beads. This scaled-down protocol was used to purify the cytoplasmic 20S proteasome of adjacent normal and tumor colorectal cells arising from tissue samples of several patients. Proteomic analyses based on two-dimensional gel electrophoresis (2DE) and mass spectrometry showed that the subunit composition of 20S proteasomes from these normal and tumor cells were not significantly different. The proteasome activity was also assessed in the cytoplasmic extracts and was similar or higher in tumor colorectal than in the corresponding normal cells. The scaled-down 20S proteasome purification protocol developed here can be applied to any human clinical tissue samples and is compatible with further proteomic analyses.
Insights
Researchers developed a new method to purify the 20S proteasome from small human tissue samples. This technique revealed similar subunit composition but altered activity in tumor colorectal cells compared to normal cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- The proteasome is crucial for intracellular protein degradation in eukaryotes.
- Proteasome dysfunction is linked to pathologies such as cancer.
- Analyzing proteasome structure and activity in clinical samples is challenging due to limited cell numbers.
Purpose of the Study:
- To optimize a scaled-down immuno-purification protocol for analyzing the 20S proteasome in human biopsy samples.
- To investigate the structure-activity relationship of the 20S proteasome in adjacent normal and tumor colorectal cells.
Main Methods:
- Development of a magnetic bead-based immuno-purification protocol for small cell samples.
- Application of the protocol to purify cytoplasmic 20S proteasomes from paired normal and tumor colorectal cells.
- Proteomic analysis using two-dimensional gel electrophoresis (2DE) and mass spectrometry.
- Assessment of proteasome activity in cytoplasmic extracts.
Main Results:
- The optimized protocol successfully purified 20S proteasomes from limited clinical tissue samples.
- Proteomic analysis showed no significant difference in the subunit composition of 20S proteasomes between normal and tumor colorectal cells.
- Proteasome activity was comparable or elevated in tumor colorectal cells relative to their normal counterparts.
Conclusions:
- The developed scaled-down protocol is effective for analyzing 20S proteasomes in human clinical tissues.
- Despite similar subunit composition, proteasome activity differs between normal and tumor colorectal cells.
- This method facilitates further proteomic investigations on clinical samples.
